Bernard Huber

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

Karsten Geletneky, Jacek Hajda, Assia L. Angelova et al. · Molecular Therapy · 2017 · 259 citations · Full text

Medicine, Immunology, Oncology +16

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

Karsten Geletneky, Johannes Huesing, Jean Rommelaere et al. · BMC Cancer · 2012 · 159 citations · Full text

Medicine, Oncology, Surgery +15

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

Jacek Hajda, Monika Lehmann, Ottheinz Krebs et al. · BMC Cancer · 2017 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Jacek Hajda, Barbara Leuchs, Assia L. Angelova et al. · Clinical Cancer Research · 2021 · 42 citations · Full text

Medicine, Immunology, Oncology +17

Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats.

Karsten Geletneky, Anne Laure Leoni, Gabriele Pohlmeyer-Esch et al. · PubMed · 2015 · 17 citations

Life Sciences, Infectious Diseases, Toxicology +12